Related Experiment Video
Updated: May 21, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma
Sijia Yan1, Xi Ming1, Rubing Zheng1
1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Background:
As a rapidly developing therapeutic method, targeted therapy plays an important role in the treatment of multiple myeloma. In recent years, mature B cell antigen-targeting therapy has brought new hope for patients with refractory/relapsed disease. While an increasing number of patients with relapse are exposed to this type of drug, changing the therapeutic target may be an effective strategy for patients with relapse/refractory multiple myeloma.
Objectives:
The expression of G protein-coupled receptor, class C Group 5 member D (GPRC5D), on the surface of myeloma tumor cells makes it a possible target for relapse/refractory multiple myeloma therapy, and relevant studies are in progress.
Results & Conclusions:
The review aims to systematically summarize the current advancements in GPRC5D-targeted therapies for multiple myeloma, thereby providing valuable insights and a foundation for future studies.
